Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS)

Abstract Introduction Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for metastatic or locally advanced urothelial carcinoma (m/laUC). Real-world patients frequently present with unfavorable clinical characteristics, raising uncertainty about whether outcomes mirror...

Полное описание

Библиографические подробности

Главные авторы:	Stefanie Zschäbitz, Irfan Bhatti, Jozefina Casuscelli, Ludwig Otto Pachmayr, Thomas Büttner, Thomas Elegeert, Nina Holzwarth, Severin Rodler, Martin Hennig, Emily Rinderknecht, Muammar Dib, Katrin Schlack, Christopher Darr, Anna-Lisa Volk, Philipp Schmucker, Friedemann Zengerling, Pia Paffenholz, Joschka Heil, Eva Erne, Subhajit Mandal, Frederik Wessels, Thea Maria Busse, Daniel Seidl, Susan Foller, Alexander Höllein, Tim Nestler, Christian Gratzke, Louis Rhode, Jakob Kohler, Günter Niegisch, Anna Katharina Seitz, Julia Heinzelbecker, Niklas Klümper, Margitta Retz, Viktor Grünwald, Can Aydogdu, Marco Julius Schnabel
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Springer 2026-07-01
Серии:	Cancer Immunology, Immunotherapy
Предметы:	Bladder cancer Enfortumab vedotin Pembrolizumab Real world evidence Urothelial carcinoma
Online-ссылка:	https://doi.org/10.1007/s00262-026-04448-2
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!